1. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes;Biftu;J. Med. Chem.,2014
2. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study;Chow;The Lancet Diabetes & Endocrinology,2018
3. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects;Christopher;Clin. Ther.,2008
4. Natural substrates of dipeptidyl peptidase IV;De Meester;Adv. Exp. Med. Biol.,2000
5. FDA., 2005. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). July 2005.www.fda.gov/downloads/Drugs/Guidance Compliance- Regulatory Information/Guidances/UCM078932.pdf. Accessed on January 21, 2014.